ArticleFrontiers in pediatrics2026
Neonatal bronchopulmonary dysplasia severity and respiratory outcomes at 3 years of age: a prospective cohort study.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To examine whether bronchopulmonary dysplasia (BPD) severity is associated with pulmonary function abnormalities and asthma diagnosis risk at 3 years of age, and to support risk-stratified respiratory follow-up in children with BPD. Methods: This prospective cohort study included 68 preterm infants admitted to the neonatal intensive care unit of The First People's Hospital of Yongkang between January 2022 and December 2022. In the study protocol, BPD was operationally defined at 36 weeks' postmenstrual age as persistent supplemental oxygen requirement [fraction of inspired oxygen (FiO2) > 0.21] to maintain target oxygen saturation of 90%-95%, together with persistent pulmonary parenchymal abnormalities on chest imaging. Severity was then categorized using a prespecified support- and oxygen-based clinical scheme informed by, but not identical to, the 2018 National Institute of Child Health and Human Development (NICHD) workshop framework. Participants were followed until 3 years of age, when conventional spirometry and guideline-based clinical asthma assessment were performed. The associations of modified BPD grade with pulmonary function indices, asthma diagnosis, and asthma clinical risk categories were analyzed. Results: Among the 68 infants with BPD, 29 (42.6%) had grade I BPD, 23 (33.8%) had grade II BPD, and 16 (23.5%) had grade III BPD. Sixty children completed both pulmonary function testing and asthma assessment at 3 years of age, yielding a follow-up rate of 88.2%. Percent predicted forced expiratory volume in 1 s (FEV1), FEV1/forced vital capacity (FVC), and maximal mid-expiratory flow (MMEF) were significantly lower in the grade III BPD group than in the grade I and grade II groups (all Conclusion: Neonatal BPD severity was associated with the degree of pulmonary function impairment and with asthma diagnosis risk at 3 years of age. Children with grade III BPD had poorer long-term respiratory outcomes and should be considered a higher-risk group requiring structured longitudinal respiratory follow-up. Because this was a selected survivor cohort with structured follow-up, and because asthma diagnosis in preschool children with BPD can overlap with post-prematurity airway disease, these findings should be interpreted as risk-marker associations rather than causal evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.